Background: Rapid drug desensitization (RDD) is a procedure that provides temporary tolerance to chemotherapeutics for appropriate patients who experience hypersensitivity reactions (HSR), which allow them to continue their treatments. Due to the labor-intensive and time-consuming nature of the commonly used multiple-bag RDD procedure, there is a need to develop an alternative protocol. We aimed to share our experiences with single-bag RDD in patients experiencing HSRs with chemotherapeutics. Methods: The study was conducted by retrospectively reviewing the files of patients who experienced immediate-type HSRs to chemotherapeutics and underwent single-bag RDD. The severity of HSRs was classified according to the Brown grading system. Prick and/or intradermal skin tests were performed with the relevant agents. The protocols were applied as a single-bag, 12-step process. Results: The study comprised 46 patients (women/men, 35/11; mean ± standard deviation age, 55.9 ± 11.9 years; 27 HSRs to platinums; 16 HSRs to taxanes; and 3 HSRs to biologic agents). Nine patients (19.6%) had an initial HSR of grade 1, 26 patients (56.5%) had an initial HSR of grade 2, and 11 patients (23.9%) had an initial HSR of grade 3. The skin testing result with the responsible drug was positive in 15 of 42 (35.7%), and the rate of positive responses in patients with grade 1, 2, and 3 initial HSRs was 37.5%, 33.3%, and 40%, respectively. A total of 163 single-bag RDDs procedures were performed, and 17 breakthrough reactions (BTR) occurred during the procedure (five of these reactions [29.5%] were grade 1; nine [53.9%] were grade 2; three [17.6%] were grade 3). Of these BTRs, 16 occurred with platinums and one with rituximab; no BTRs were observed with taxanes. In conclusion, 99.3% of the total 163 single-bag RDD procedures were successfully completed. Conclusion: Our experience indicates that single-bag RDD can be a safe and effective alternative that saves time and labor in appropriate patients.

背景：快速药物脱敏（RDD）是一种为经历过敏反应（HSR）的适当患者提供对化疗药物临时耐受性的程序，这使他们能够继续治疗。由于常用的多袋RDD程序劳动密集且耗时长，有必要开发替代方案。我们旨在分享我们在经历HSRs患者中使用单袋RDD的经验。方法：该研究通过回顾性审查经历过即时型HSRs并对化疗药物进行单袋RDD的患者的文件来开展。根据Brown分级系统对HSRs的严重程度进行了分类。对于相关药物进行了点刺和/或皮内皮肤测试。该方案采用了一种包含12个步骤的单袋程序。结果：研究共包括46名患者（女性/男性，35/11；平均±标准差年龄，55.9 ± 11.9岁；27例对铂类药物HSRs；16例对紫杉烷类药物HSRs；3例对生物制剂HSRs）。有9名患者（19.6%）最初发生的HSR为1级，26名患者（56.5%）最初的HSR为2级，11名患者（23.9%）的初始HSR为3级。在42例中有15例（35.7%）对负责药物的皮肤测试结果呈阳性，对于1级、2级和3级初始HSRs患者的阳性反应率分别为37.5%，33.3% 和 40%。共进行了163次单袋RDD程序，在此过程中发生了17例突破性反应（BTR）（其中5例[29.5%]为1级；9例[53.9%]为2级；3例[17.6%]为3级）。在这17个BTR中，有16个发生在铂类药物使用过程中，一个发生在利妥昔单抗使用过程中，没有在紫杉烷类药物使用过程中观察到BTR。总的来说，99.3%的总共163次单袋RDD程序成功完成。结论：我们的经验表明，在适当患者中，单袋RDD可以作为一种节省时间和劳动的安全有效替代方案。